Zika Virus Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Zika Virus Infections – Pipeline Review, H2 2017’, provides an overview of the Zika Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Zika Virus Infections

The report reviews pipeline therapeutics for Zika Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Zika Virus Infections therapeutics and enlists all their major and minor projects

The report assesses Zika Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Zika Virus Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Zika Virus Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Zika Virus Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Acuitas Therapeutics Inc

Bharat Biotech International Ltd

BioCryst Pharmaceuticals Inc

Biotron Ltd

CaroGen Corp

Cocrystal Pharma Inc

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

Etubics Corp

GeneOne Life Science Inc

GeoVax Labs Inc

Gilead Sciences Inc

GT Biopharma Inc

Hawaii Biotech Inc

Heat Biologics Inc

Hemispherx Biopharma Inc

Immunovaccine Inc

Johnson & Johnson

Kineta Inc

Moderna Therapeutics Inc

Mymetics Corp

NewLink Genetics Corp

Novalex Therapeutics Inc

Novavax Inc

PaxVax Inc

PlantForm Corp

Plex Pharmaceuticals Inc

Profectus BioSciences Inc

Prokarium Ltd

Replikins Ltd

Sanofi

Sirnaomics Inc

Spotlight Innovation Inc

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

Tamir Biotechnology Inc

TechnoVax Inc

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

VBI Vaccines Inc

VLP Therapeutics LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Zika Virus Infections Overview 6

Zika Virus Infections Therapeutics Development 7

Zika Virus Infections Therapeutics Assessment 19

Zika Virus Infections Companies Involved in Therapeutics Development 27

Zika Virus Infections Drug Profiles 46

Zika Virus Infections Dormant Projects 160

Zika Virus Infections Discontinued Products 161

Zika Virus Infections Product Development Milestones 162

Appendix 174

List of Tables

List of Tables

Number of Products under Development for Zika Virus Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Zika Virus Infections Pipeline by Abivax SA, H2 2017

Zika Virus Infections Pipeline by Acuitas Therapeutics Inc, H2 2017

Zika Virus Infections Pipeline by Bharat Biotech International Ltd, H2 2017

Zika Virus Infections Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Zika Virus Infections Pipeline by Biotron Ltd, H2 2017

Zika Virus Infections Pipeline by CaroGen Corp, H2 2017

Zika Virus Infections Pipeline by Cocrystal Pharma Inc, H2 2017

Zika Virus Infections Pipeline by Emergent BioSolutions Inc, H2 2017

Zika Virus Infections Pipeline by Ennaid Therapeutics LLC, H2 2017

Zika Virus Infections Pipeline by Etubics Corp, H2 2017

Zika Virus Infections Pipeline by GeneOne Life Science Inc, H2 2017

Zika Virus Infections Pipeline by GeoVax Labs Inc, H2 2017

Zika Virus Infections Pipeline by Gilead Sciences Inc, H2 2017

Zika Virus Infections Pipeline by GT Biopharma Inc, H2 2017

Zika Virus Infections Pipeline by Hawaii Biotech Inc, H2 2017

Zika Virus Infections Pipeline by Heat Biologics Inc, H2 2017

Zika Virus Infections Pipeline by Hemispherx Biopharma Inc, H2 2017

Zika Virus Infections Pipeline by Immunovaccine Inc, H2 2017

Zika Virus Infections Pipeline by Johnson & Johnson, H2 2017

Zika Virus Infections Pipeline by Kineta Inc, H2 2017

Zika Virus Infections Pipeline by Moderna Therapeutics Inc, H2 2017

Zika Virus Infections Pipeline by Mymetics Corp, H2 2017

Zika Virus Infections Pipeline by NewLink Genetics Corp, H2 2017

Zika Virus Infections Pipeline by Novalex Therapeutics Inc, H2 2017

Zika Virus Infections Pipeline by Novavax Inc, H2 2017

Zika Virus Infections Pipeline by PaxVax Inc, H2 2017

Zika Virus Infections Pipeline by PlantForm Corp, H2 2017

Zika Virus Infections Pipeline by Plex Pharmaceuticals Inc, H2 2017

Zika Virus Infections Pipeline by Profectus BioSciences Inc, H2 2017

Zika Virus Infections Pipeline by Prokarium Ltd, H2 2017

Zika Virus Infections Pipeline by Replikins Ltd, H2 2017

Zika Virus Infections Pipeline by Sanofi, H2 2017

Zika Virus Infections Pipeline by Sirnaomics Inc, H2 2017

Zika Virus Infections Pipeline by Spotlight Innovation Inc, H2 2017

Zika Virus Infections Pipeline by Starpharma Holdings Ltd, H2 2017

Zika Virus Infections Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Zika Virus Infections Pipeline by Tamir Biotechnology Inc, H2 2017

Zika Virus Infections Pipeline by TechnoVax Inc, H2 2017

Zika Virus Infections Pipeline by Themis Bioscience GmbH, H2 2017

Zika Virus Infections Pipeline by Theravectys SA, H2 2017

Zika Virus Infections Pipeline by Valneva SE, H2 2017

Zika Virus Infections Pipeline by Vaxart Inc, H2 2017

Zika Virus Infections Pipeline by VBI Vaccines Inc, H2 2017

Zika Virus Infections Pipeline by VLP Therapeutics LLC, H2 2017

Zika Virus Infections Dormant Projects, H2 2017

Zika Virus Infections Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Zika Virus Infections, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports